Gastroenterology

Millie Long discusses treatment considerations for Crohn’s Disease (CD) patients who are planning for pregnancy.

NLR values were similar between significant and minimal fibrosis and were not correlated with significant fibrosis.

Patients with anti-HDV antibodies had a significantly higher prevalence of liver cirrhosis, significantly lower prothrombin time, and a higher prevalence of HIV co-infection compared to patients who demonstrated serum anti-HDV antibody negatively.

Men who have sex with men in Europe were more likely to be in a cluster compared to non-European men who have sex with men.

The US Food and Drug Administration (FDA) approved linaclotide earlier this month for the treatment of patients with functional constipation aged 6-17 years.

The race-neutral model resulted in worse calibration, NPV, and false-negative rates among racial and ethnic minority subgroups compared to non-Hispanic White participants.

There were no new safety signals identified from the COMMAND trial.

Noting that global elimination of HCV will require a commitment from individual communities, Mamta Jain, MD, MPH, discusses the role of primary care providers in the care spectrum.

Mamta Jain, MD, MPH, summarizes community outreach efforts regarding the training and education of health workers.

Parvez Mantry, MD, examines the question of why so many patients with HCV do not undergo therapy. He also discusses policy updates aimed at improving screening and expanding access to treatment.

Parvez Mantry, MD, discusses the burden of HCV and challenges to diagnosis and therapy. He also explores general awareness regarding HCV and opportunities for screening.

In the maintenance period, 86% of patients treated icanbelimod completed and 67% achieved clinical remission through week 48.

Experts discuss the results of a five-year efficacy and safety trial of ustekinumab for treatment of Crohn’s Disease (CD).

Anita Afzali, MD, David Hudesman, MD, Millie Long, and Miguel Regueiro, MD, discuss Vedolizumab and Risankizumab as treatments for Crohn’s Disease (CD).

The point prevalence per 100,000 people at the conclusion of the study was 71.8 for autoimmune hepatitis, 38.5 for primary biliary cholangitis, and 11.0 for primary sclerosing cholangitis.

For individuals with hepatitis C virus infections, 52.5% of deaths were deemed attributable to the infection.

Patients with autoimmune hepatitis who were positive for antimitochondrial antibodies and evidence of non-specific bile duct injury had a higher risk of progressing to cirrhosis.

The possibility of clients reacting dismissively and of unsettling clients were viewed as the main barriers preventing better screening within these populations.

The treatment represents the first approval for pediatric patients with functional constipation.

After they adjusted for manufacturer rebates to estimate net prices, the investigators fund HCV drug prices decreased by 31% from 2013-2020.

David Hudesman, MD, Miguel Regueiro, MD, and Maia Kayal, MD, offer first line treatment strategies for patients with Crohn’s Disease (CD).

Experts discuss how to care for Inflammatory Bowel Disease (IBD) patients who are not responding to treatment.

The area under the concentration-time curve (AUC) for vancomycin at discharge was the only modifiable factor found that was independently associated with patient safety outcomes.

The most frequent mutations found in the analyzed genomes was fluoroquinolone-associated mutations such as gyrA and there were 24 different sequence types were identified in the 130 isolates.

Experts discuss treatment options for patients with Inflammatory Bowel Disease (IBD) and clinical factors to consider.